IL1B and systemic-onset juvenile idiopathic arthritis: IL-1β inhibitors, such as rilonacept and canakinumab, have shown promise in reducing lung cancer incidence and mortality, as well as in the treatment of autoinflammatory relapsing fever syndrome and Still’s disease (56).